J&J's Zytiga put on fast track for broader use; AZ superbug antibiotic wins clearance in EU;

 @FiercePharma: Primary-care sales reps may have a tough time seeing their docs, but cancer reps? Talk to the hand--PharmaTimes. Report | Follow @FiercePharma

> Johnson & Johnson's ($JNJ) prostate cancer drug Zytiga won fast-track review for a new use in patients who haven't been treated with chemotherapy yet. Report

> AstraZeneca's ($AZN) superbug-fighter Zinforo won approval from European regulators; it's marketed in the U.S. by Forest Laboratories under the brand name Teflaro. Report

> Johnson & Johnson's pain drug Nucynta won FDA approval for a new use in diabetic peripheral neuropathy, becoming the first opioid for that indication. Release

> Denmark's Lundbeck said its blood cancer drug Treanda won approval for marketing in Canada. Report

> Strides Arcolab subsidiary Onco Therapies won FDA approval for its version of GlaxoSmithKline's ($GSK) cancer treatment Hycamtin. Report

> Russia's top drugmaker, Pharmstandard, saw earnings drop by 27% to about $96 million for the first half of the year, as revenues dropped 13.3%. Report

> Troubled Russian pharmacy chain 36.6 reported bigger losses on discounts, as its drug subsidiary Veropharm suffered from higher taxes on flat sales. Report

> New cancer treatments accounted for 115 of Australia's 795 new drug approvals over the past decade. Report

Medical Device News

 @FierceMedDev: Evidence is building that MRI scans can be safe for people with pacemakers or implanted defibrillators--via Reuters. Article | Follow @FierceMedDev

 @MarkHFierce: TAVI works well for some patients, a new study concludes--a boost for tech made by Edwards, Medtronic and others. Report | Follow @MarkHFierce

 @DamianFierce: OmniGuide pulled in $35M from OrbiMed to market its laser surgery devices. More | Follow @DamianFierce

> Japan may be key to further propelling Resolute stent sales. Article

> St. Jude says its hypertension tech beats Medtronic, Covidien. Story

Biotech News

 @FierceBiotech: Tech startup waltzes with wireless giant in Africa to expand mobile anti-drug counterfeiting system. Article | Follow @FierceBiotech

 @JohnCFierce: ArQule tanks after tox fears force a delay in Asian lung cancer study. News | Follow @JohnCFierce

 @RyanMFierce: Achillion M&A talk again post BMS setback with Hep C nuc, but I'm thinking after BMS' M&A debacle pharma won't be so trigger-happy with deals. More | Follow @RyanMFierce

> Hot M&A trend in biopharma spurs surge in insider trading cases. Story

> Strike three: Bad data bury Eli Lilly's late-stage schizophrenia drug. Article

> Boom times for the regulatory affairs profession. Item

> Big Pharma betting billions in high-stakes hunt for the next Lipitor. Report

Biomarkers News

> Genentech and academics spot colon cancer gene markers. More

> For glioma, it's all in the letters. Story

Drug Delivery News

> Proteonomix licenses out cells that deliver anti-cancer factors. More

> Silence is golden: U.K. RNAi player signs delivery pact with MiReven. Article

> Cisplatin liposomes cut side effects. Item

And Finally... Infants given antibiotics were more likely to be overweight as youngsters, a study found. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.